Collaborative drug therapy management for initiating and adjusting insulin therapy in patients with type 2 diabetes mellitus

American Journal of Health-System Pharmacy

Volumn 67, Issue 1, 2010, Pages 42-48

  Rochester, Charmaine D ^a   Leon, Nicholas ^a   Dombrowski, Robert ^b   Haines, Stuart T ^c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b CENTERS FOR MEDICARE AND MEDICAID SERVICES   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Ambulatory care; Antidiabetic agents; Clinical pharmacists; Clinical pharmacy; Department of Veterans Affairs; Diabetes mellitus; Dosage; Insulin; Insulins; Patient information; Pharmaceutical services; Protocols

Indexed keywords

HEMOGLOBIN A1C; HYPERGLYCEMIC AGENT; INSULIN; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; ALGORITHM; ARTICLE; CLINICAL ARTICLE; DIABETES CONTROL; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH CENTER; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; LIFESTYLE MODIFICATION; MALE; MEDICAL DECISION MAKING; MEDICATION THERAPY MANAGEMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT EDUCATION; PHARMACEUTICAL CARE; PHARMACIST; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SELF CARE; SELF MONITORING; TREATMENT RESPONSE;

EID: 74049095107     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp080706     Document Type: Article

References (39)

1. Hammond RW, Schwartz AH, Campbell MJ et al. Collaborative drug therapy management by pharmacist - 2003. Pharmacotherapy. 2003; 23:1210-25.
2. Status of collaborative drug therapy management in the United States. Am J Health-Syst Pharm. 2004; 61:1609-10.
3. Goode JV. Change in community pharmacy practice - it is not just coming from the cash register. US Pharm Rev. 2006; August:1-4.
4. Massachusetts Pharmacy Association. Governor signs collaborative drug therapy management. www.masspharmacists.org/displaycommon.cfm?an= 1&subarticlenbr=27 (accessed 2009 Mar 30).
5. American Diabetes Association. Standards of medical care in diabetes - 2009. Diabetes Care. 2009; 32(suppl 1):S13-61.
6. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007; 13:1-68.
7. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352:837-53. [Erratum, Lancet. 1999; 354:602.]
8. De Witt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: a scientific review. JAMA. 2003; 289:2254-64.
9. Ong KL, Cheung BM, Man YB et al. Treatment and control of diabetes mellitus in the United States National Health and Nutrition Examination Survey, 1999-2002. J Cardiometab Syndr. 2006; 1:301-7.
10. Vivian EM. The pharmacist's role in maintaining adherence to insulin therapy in type 2 diabetes mellitus. Consult Pharm. 2007; 22:320-32.
11. Peyrot M, Rubin RR, Lauritzen T et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes and Needs (DAWN) study. Diabetes Care. 2005; 28:2673-9.
12. Kroon LA, Coleman LT, Koda-Kimble MA. The management of type 2 diabetes mellitus: a call to action for pharmacists. US Pharm. 1997; 22(suppl 1):1-18.
13. Fera T, Bluml BM, Ellis WM et al. The diabetes ten city challenge: interim clinical and humanistic outcomes of a multisite community pharmacy diabetes care program. J Am Pharm Assoc. 2008; 48:181-90.
14. Nkansah NT, Brewer JM, Connors R et al. Clinical outcomes of patients with diabetes mellitus receiving medication management by pharmacists in an urban private physician practice. Am J Health-Syst Pharm. 2008; 65:145-9.
15. Brooks AD, Rihani RS, Derus CL. Pharmacist membership in a medical group's diabetes health management program. Am J Health-Syst Pharm. 2007; 64:617-21.
16. Kiel PJ, McCord AD. Pharmacist impact on clinical outcomes in a diabetes disease management program via collaborative practice. Ann Pharmacother. 2005; 39:1828-32.
17. Leal S, Soto M. Chronic kidney disease risk reduction in a Hispanic population through pharmacist-based disease-state management. Adv Chronic Kidney Dis. 2008; 15:162-7.
18. Garrett DG, Bluml BM. Patient self-management program for diabetes: first year clinical, humanistic and economic outcomes. J Am Pharm Assoc. 2005; 45:130-7.
19. Cranor CW, Christensen DB. The Asheville Project: factors associated with outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc. 2003; 43:160-72.
20. Irons BK, Seifert FC, Horton NA. Quality of care of a pharmacist-managed diabetes service compared to usual care in an indigent clinic. Diabetes Technol Ther. 2008; 10:220-6.
21. Leal S, Glover JJ, Herrier RN et al. Improving quality of care in diabetes through a comprehensive pharmacist-based disease management program. Diabetes Care. 2004; 27:2983-4.
22. Leal S, Soto M. Pharmacists disease state management through a collaborative practice model. J Health Care Poor Underserved. 2005; 16:220-4.
23. Wubben DP, Vivian E. Effects of pharmacist outpatient interventions on adults with diabetes mellitus: a systematic review. Pharmacotherapy. 2008; 28:421-36.
24. Bodenheimer T. Primary care - will it survive? N Engl J Med. 2006; 355:861-4.
25. O'Mara NB. Insulin use in patients with type 2 diabetes. Pharm Lett Prescr Lett. 2008; 24:241101.
26. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2009; 32:1-11.
27. Carmichael JM, O'Connell MB, Devine B et al. Collaborative drug therapy management by pharmacists. Pharmacotherapy. 1997; 17:1050-61.
28. Riddle MC, Rosenstock J, Gerich J et al. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003; 26:3080-6.
29. Lebovitz HE, Austin MM, Blond L et al. ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations. Endocr Pract. 2006; 12:6-8.
30. Riddle MC. Timely initiation of basal insulin. Am J Med. 2004; 116 (suppl 3A):3S-9S.
31. Wright A, Burden AC, Paisey RB et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002; 25:330-6.
32. Hayward RA, Manning WG, Kaplan SH et al. Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization. JAMA. 1997; 278:1663-7.
33. Riddle MC. Evening insulin strategy. Diabetes Care. 1990; 13:676-86.
34. Selam JL, Koenen C, Weng W et al. Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naive patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study. Curr Med Res Opin. 2008; 24:11-20.
35. 1c on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006; 29:1-8.
36. Choe HM, Mitovich S, Dubay D et al. Proactive case management of high risk patients with type 2 diabetes by a clinical pharmacist: a randomized, controlled trial. Am J Manag Care. 2005; 11:253-60.
37. Martin OJ, Wu W, Schleintz MD et al. Effectiveness of pharmacist-coordinated care to reduce cardiovascular risk factors in patients with diabetes mellitus. Circulation. 2004; 109:P203. Abstract.
38. Taveira TH, Wu WC, Martin OJ et al. Pharmacist-led cardiac risk reduction model. Prev Cardiol. 2006; 9:202-8.
39. Funnell MM, Tang TS, Anderson RM. From DSME to DSMS: developing empowerment based diabetes self-management support. Diabetes Spectr. 2007; 20:221-6.